BrainsWay to Report Third Quarter 2025 Financial Results on November 11, 2025
BURLINGTON, Mass. and JERUSALEM, Oct. 28, 2025 (GLOBE NEWSWIRE) -- BrainsWay Ltd. (NASDAQ & TASE: BWAY) (“BrainsWay” or the “Company”),...
Clinical Trial
Pacira BioSciences Presents Updated Three-Year Data Demonstrating Sustained Efficacy and Safety of PCRX-201 Gene Therapy for Patients with Moderate-to-Severe Osteoarthritis of the Knee
-- Data demonstrates sustained clinical improvements in pain, stiffness and function for up to 156 weeks following a single administration...
Glucotrack, Inc. Reminds Shareholders to Vote
The Special Meeting of Shareholders held on October 31, 2025 Shareholders vote on Equity Purchase Agreement with Sixth Borough Capital Fund...
CervoMed Strengthens Board with Appointment of Life Sciences Business Strategy Leader David Quigley
Mr. Quigley most recently led McKinsey & Company’s Private Capital practice and previously led various Life Sciences practices at the...
ORYZON Strengthens Regulatory Strategy with the Appointment of Dr. Iman Barilero as Senior Advisor for Regulatory Affairs
To enhance and accelerate regulatory dialogue with the FDA To provide strategic guidance across clinical development programsTo bring deep expertise...
Madrigal to Present New Data from the Company’s MASH Program at AASLD’s The Liver Meeting 2025
Two oral presentations to highlight biomarker, imaging and quality-of-life data from the open-label compensated MASH cirrhosis (F4c) arm of the...
Orchestra BioMed and Terumo Enter into New $30 Million Virtue SAB Strategic Agreements
New agreement grants Terumo Virtue SAB coronary indication right of first refusal and supersedes prior distribution agreementTerumo to pay a...
OPKO Health’s ModeX Therapeutics Begins Clinical Trial of MDX2004 for the Treatment of Advanced Cancers
First patient dosed in Phase 1/2a study with novel immune rejuvenator, a trispecific antibody-fusion protein Two MDX2004 abstracts accepted for...
Edesa Biotech Reports Positive Results in Phase 3 Respiratory Study
Study met primary and secondary endpointsParidiprubart demonstrated a relative reduction in the risk of death of 25%Treatment provided patients with...
Kiniksa Pharmaceuticals Reports Third Quarter 2025 Financial Results and Recent Portfolio Execution
– ARCALYST® (rilonacept) Q3 2025 net product revenue of $180.9 million, representing 61% year-over-year growth –– ARCALYST 2025 expected net...
TG Therapeutics Completes Enrollment in the Phase 3 ENHANCE Trial Evaluating its New Simplified Dosing Schedule for BRIUMVI
NEW YORK, Oct. 28, 2025 (GLOBE NEWSWIRE) -- TG Therapeutics, Inc. (NASDAQ: TGTX), announced today that enrollment has completed in...
Invivyd to Host Webcast on the REVOLUTION Clinical Program for VYD2311, a Vaccine-Alternative Antibody to Prevent COVID
NEW HAVEN, Conn., Oct. 28, 2025 (GLOBE NEWSWIRE) -- WHAT: Invivyd, Inc. (Nasdaq: IVVD) is hosting the previously announced live...
Causeway Therapeutics Debuts Positive Data from Phase 2 Clinical Trial of TenoMiR® for Lateral Epicondylitis
Data Show Statistically Significant Improvements in Pain, Function and Tendon Structure in Appropriately Dosed PatientsGLASGOW, Scotland, Oct. 28, 2025 (GLOBE...
ONL Therapeutics Announces Randomization of First Patient in Global Phase 2 GALAXY Trial of Xelafaslatide (ONL1204) in Patients with Geographic Atrophy (GA) Associated with Dry AMD
Approvals received from World Health Organization and United States Adopted Names Council establishing “xelafaslatide” as nonproprietary name for ONL1204 Ophthalmic...
Izotropic Launches “Breast Imaging News” Page on BreastCT.com
Vancouver, British Columbia, and Sacramento, California--(Newsfile Corp. - October 28, 2025) - Izotropic Corporation (CSE: IZO) (OTCQB: IZOZF) (FSE: 1R3)...
IR-MED’s Key Clinical and Media Milestones
PressureSafe(TM) clinical results presented to global nursing leaders; the Company engages with U.S. investment community and national media in parallel...
Electronic Trial Master File (eTMF) Systems Market worth $2.49 billion by 2030 with 12.8% CAGR | MarketsandMarkets™
DELRAY BEACH, Fla., Oct. 27, 2025 /PRNewswire/ -- The global Electronic Trial Master File (eTMF) Systems Market, valued at US$1.21 billion...
NanoViricides to Present at the PODD 2025 Conference in Boston on October 27
SHELTON, CT / ACCESS Newswire / October 27, 2025 / NanoViricides, Inc. (NYSE American: NNVC ) (the "Company"), a clinical...
NanoViricides to Present at the PODD 2025 Conference in Boston on October 27
SHELTON, CT / ACCESS Newswire / October 27, 2025 / NanoViricides, Inc. (NYSE American: NNVC ) (the "Company"), a clinical...
NanoViricides to Present at the PODD 2025 Conference in Boston on October 27
SHELTON, CT / ACCESS Newswire / October 27, 2025 / NanoViricides, Inc. (NYSE American: NNVC ) (the "Company"), a clinical...